A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood
Citations
180 citations
Cites background from "A Review of Fluid Biomarkers for Al..."
...It is noteworthy, however, that increased NFL is not specific to AD, serving as a biomarker for other causes of neurodegeneration (Blennow, 2017)....
[...]
152 citations
Cites background from "A Review of Fluid Biomarkers for Al..."
...are found primarily in the CSF, and to a lesser extent in blood [47]....
[...]
130 citations
117 citations
Cites background from "A Review of Fluid Biomarkers for Al..."
...Relatively accurate diagnosis and timely therapies will likely be achieved when neuropsychological, fluid and imaging biomarkers are used in combination (Viola and Klein, 2015; Dubois et al., 2016; Blennow, 2017)....
[...]
108 citations
References
4,020 citations
"A Review of Fluid Biomarkers for Al..." refers background in this paper
...Synaptic degeneration and loss is one of the best pathoanatomical correlates of cognitive deficits in AD and predicts disease better than Ab plaque load [30, 31]....
[...]
3,951 citations
2,581 citations
"A Review of Fluid Biomarkers for Al..." refers background in this paper
...Since two amyloid biomarkers are included in the updated International Working Group (IWG-2) criteria [22], there is a need to understand if they give complementary information, or if they can be used interchangeably....
[...]
...A revised and updated version of these criteria was published in 2014, the main difference being that downstream topographical biomarkers (volumetric MRI and FDG-PET), were not included among core diagnostic biomarkers (now restricted to amyloid PET and the CSF biomarkers) but only used for monitoring disease course or stage [22]....
[...]
2,076 citations
1,983 citations
"A Review of Fluid Biomarkers for Al..." refers background in this paper
...Furthermore, the Phase1b aducanumab trial showed a doseand time-dependent reduction in brain amyloid plaques as measured by florbetapir PET, but also a high frequency of amyloid-related imaging abnormalities (ARIA) [19]....
[...]
...Thus, given that we may soon have effective, but most likely also expensive, drugs that may give side-effects such as ARIA, and that mild cognitive impairment (MCI) is a heterogeneous syndrome caused by many disorders (only around half of cases have AD), there is a large need for biomarker-based diagnostic criteria that allow an accurate diagnosis of AD already during the MCI stage, for review see [20]....
[...]